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Abstract
The transcription factor nuclear factor-κB (NF-κB) is a central mediator of growth and homeostasis for both normal
and neoplastic cells. IκBα is the natural intracellular inhibitor of NF-κB and can effectively complex with and thereby
inhibit the biologic activity and translocation of NF-κB to the nucleus. We designed a fusion protein designated
IκBα/scFvMEL composing of human IκBα and the single-chain antibody scFvMEL, targets melanoma gp240 anti-
gen. Cells treated with IκBα/scFvMEL before irradiation showed specifically inhibition of both constitutive and
radiation-induced NF-κB activity on gp240 antigen–positive A375M cells. Pretreatment of A375M cells with IκBα/
scFvMEL significantly sensitized melanoma cells to ionizing radiation assessed using a clonogenic survival assay.
Mechanistic studies showed that IκBα/scFvMEL, when exogenously added to A375M cells, could be coimmuno-
precipitated with the p65 subunit of NF-κB. IκBα/scFvMEL inhibited in a time and/or dose-dependent manner of
tumor necrosis factor α– or radiation-induced NF-κB activity in vitro. IκBα/scFvMEL was also shown to specifically
inhibit the translocation of the NF-κB p65 subunit to the cell nucleus and NF-κB–mediated gene transcription. Further,
initial studies showed that mice bearing well-established A375M xenografts were treated (intravenously) with IκBα/
scFvMEL and showed a significant suppression of tumor growth. We also observed a decrease in levels of Bcl-2
and Bcl-XL signaling events downstream of NF-κB in the tumor model. These studies demonstrate for the first time
that tumor cell–targeted delivery of IκBα may be beneficial for the treatment of melanoma when combined with
standard anticancer therapies such as radiation.
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Introduction
Recent advances in the understanding of the underlying biology in the
progression of melanoma have identified key signaling pathways that
are important in promoting melanoma tumorigenesis, thus providing
dynamic targets for therapy. One such important target identified in
melanoma tumor progression is the nuclear factor-kappa B (NF-κB)
pathway [1,2]. The nuclear transcription factor NF-κB is an inducible
dimer whose biologic activity is tightly controlled by numerous cellular
signal transduction cascades [3,4]. This is a central control pathway
responsible for normal and neoplastic cell growth and is involved in
various pathways such as cytokine synthesis and release, intracellular
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signaling, and the inflammatory response in both normal and patho-
logic conditions. NF-κB complexes are typically retained in the cyto-
plasm by binding inhibitory IκB proteins (including IκBα) into a
ternary, inactive complex. On stimulation, IκBα is rapidly phosphor-
ylated and degraded through the ubiquitin-proteasome pathway and
the released dimeric p65/p50 complex becomes active and free NF-κB
translocates to and accumulates within the nucleus where it is free to
associate with cognate κB elements in target gene promoters.
Many human solid tumor cell lines display increased endogenous
nuclear NF-κB levels and/or increased NF-κB transcriptional activity.
NF-κB is frequently found to be constitutively activated in Hodgkin
lymphoma, head and neck squamous cell carcinoma, non–small cell
lung cancer, colorectal cancer, thyroid cancer, pancreatic carcinoma, leu-
kemia, multiple myeloma, prostrate cancer, and breast cancer [5–7].
Several laboratories have also previously shown constitutive NF-κB ex-
pression in melanoma cells [8]. In most nontransformed cell types,
NF-κB complexes (a heterotrimer composed of p50 and RelA/p65
subunits bound to an inhibitor, IκB) are largely cytoplasmic. Not sur-
prisingly, tumor progression and metastatic spread have been linked
to up-regulation of NF-κB activity. Because the NF-κB pathway seems
to be a central mediator for growth regulation, cytokine production, and
apoptosis modulation. Several studies have suggested that this may
represent an excellent potential target for therapeutic intervention [9–
13]. Regulation of NF-κB is important for the physiology of inflam-
mation and immune activation, and misregulation of NF-κB activity
has been identified as a major culprit of chronic inflammatory diseases
and cancer.
The gp240 antigen (also known as the high–molecular weight
melanoma-associated antigen) is well expressed on a high percentage
of melanoma cell lines and on melanoma tumor biopsy specimens
[5–7]. Several monoclonal antibodies (mAbs) that target this antigen
have been developed [8,14–16], and a variety of recombinant fusion con-
structs have been generated from the murine Ab designated ZME-018,
which targets this protein [17,18]. A recombinant, single-chain construct
designated scFvMEL has been successfully used by our laboratory to
deliver a number of therapeutic agents to the cytoplasm of melanoma
cells. Because activated NF-κB is a critical mediator of cell growth in
melanoma, we proposed that regulation of this pathway in melanoma
may be of particular importance. We therefore designed a fusion con-
struct composed of the scFvMEL Ab fused to the natural cellular in-
hibitor of NF-κB designated IκBα. This article reports the first studies
of this novel fusion construct designed to regulate NF-κB activity in
tumor-targeted cells, and this represents a potentially new class of tar-
geted therapeutic agents.
In this report, we describe the characterization and mechanism of
IκBα/scFvMEL to inhibit NF-κB intracellular activity in vitro and
in vivo. We demonstrated that IκBα/scFvMEL can be specifically in-
ternalized into gp240-positive melanoma cells, associate with NF-κB
complexes, inhibit NF-κB binding activity and p65 translocation,
and inhibit NF-κB–mediated transcription. We demonstrated that
targeting treatment with IκBα/scFvMEL inhibited both constitutive
and radiation-induced NF-KB activity in melanoma. Clonogenic cell
survival assays showed that pretreatment with IκBα/scFvMEL en-
hanced tumor cell radiosensitivity. Further, in vivo studies showed
that mice bearing well-established A375M xenografts treated with
IκBα/scFvMEL significantly suppressed tumor growth. These studies
support the concept of using IκBα as a novel payload in targeted ther-
apeutic constructs for the selective and specific inhibition of NF-κB
activity in target cells.
Materials and Methods
Materials
Bacterial strains, pET-32a bacterial expression plasmid, and throm-
bin were obtained fromNovagen (Madison,WI).Hi-Trap chelatingHP
resin and other chromatography resins were purchased from Amersham
Biosciences (Uppsala, Sweden). Abs to anti-IκBα, anti-Bcl2, anti–Bcl-
xL, anti-Bax, anti–NF-κB p65, anti–NF-κB p50, anti-PARP, anti–β-
actin, and protein G PLUS-agarose were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). FuGENE 6 transfection reagent
was obtained from Life Technologies, Inc (Rockville, MD). Recombi-
nant human tumor necrosis factor α (TNFα) were purchased from
R&D Systems (Minneapolis, MN). Alexa Fluor 488 goat antirabbit im-
munoglobulin G (IgG) was purchased from Invitrogen (Grand Island,
NY). Fluorescein isothiocyanate (FITC)–coupled antirabbit IgG were
purchased from Sigma (St Louis, MO). Alexa Fluor 594 goat antirabbit
IgG was purchased from Molecular Probes (Eugene, OR). Horseradish
peroxidase (HRP)–conjugated goat antirabbit IgG was purchased from
Bio-Rad (Hercules, CA).
Cell Lines and Cell Culture
The human promyelocytic cell line HL-60 obtained from ATCC
were routinely maintained in Iscove’s modified Dulbecco’s medium
with 4mML-glutamine and 20% fetal bovine serum.Different human
melanoma cell lines A375M, A375SM, AAB527, and TXM-1 were
obtained from Dr I. J. Fidler (MD Anderson Cancer Center, Houston,
TX). A375M, A375SM, andAAB-527 cells were cultured inDulbecco’s
modified Eagle medium, TXM-1 were cultured in minimum essential
medium (MEM), and the bladder cell line T-24 was obtained from
American Type Culture Collection (Manassas, VA) and maintained in
McCoy’s 5Amedium containing 10% fetal bovine serum, with added so-
dium pyruvate (1 mM), nonessential amino acids (0.1 mM), L-glutamine
(2 mM), and MEM vitamins.
Construction of IκBα/scFvMEL Fusion Gene
The human IκBα gene was cloned from HL-60 RNA by reverse
transcription–polymerase chain reaction (RT-PCR), and DNAwas se-
quenced. The fusion construct was designed in the IκBα-G4S linker-
scFvMEL format. The construction was based on an overlapping PCR
method. The IκBα gene was amplified by PCR using the primers
NTXIÊB (5′-3′) CTGGTGCCACGCGGTTCTTTCCAGG-
CGGCCGAGCGC and CG4SIÊB (5′-3′) GGAGCCACCGCCAC-
CTAACGTCAGACGCTG. These were designed to insert a thrombin
cleavage site at the NH2 terminus. The scFvMEL gene was amplified by
PCR from plasmid pET32-scFvMEL/TNF as previously described
[17]. The fused IκBα/scFvMEL genes were linked together by using
primers NTXIÊB and CH3MEL. To clone the fused genes into
pET-32a (+) vector with thrombin cleavage site at the NH2 terminus
of IκBα, the fragment from pET-32a (+) was amplified by using the
primers T7 promoter (5′-3′) TAATACGACTCACTATAG and
CPETTX (5′-3′) AGAACCGCGTGGCACCAGACCAGAAGAATG.
The IκBα/scFvMEL fusion gene was then cloned into the pET-32a (+)
vector at XbaI and HindIII, designated pET-32 IκBα/scFvMEL.
Expression and Purification of the IκBα/scFvMEL Construct
Escherichia coli Origami DE3 cells (Novagen, Inc) was used to ex-
press protein from pET-32 IκBα/scFvMEL. A 5-ml aliquot of a stock
culture grown overnight was used to inoculate flasks containing 500ml
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of Luria-Bertani containing 400 μg/ml carbenicillin, 15 μg/ml kana-
mycin, and 15 μg/ml tetracycline. Cultures were agitated at 240 rpm
until A600 nm = 1.0 at 37°C and then diluted 1:1 with fresh medium
plus antibiotics. Expression was induced by addition of isopropyl β-D-
thiogalacto-pyranoside to a 100-μM concentration at 18°C overnight.
Cells were harvested by centrifuging at 5000 rpm for 20 minutes and
were stored frozen.
Cell pellets containing His-tagged IκBα/scFvMELwere resuspended
in 20 mMTris-HCl (pH 8.0) and 200 mMNaCl. Cells were disrupted
with Microfluidizer (Newton, MA), and lysates were centrifuged at
40,000 rpm at 4°C for 30 minutes. The supernatant containing only
soluble protein loaded onto a cobalt-charged metal-affinity column.
The column was washed with 50 column volumes of 20 mM Tris-
HCl (pH 8.0), 200 mM NaCl, 20 mM imidazole containing 0.1%
of Triton X-114 (Sigma-Aldrich, Deisenhofen, Germany) and then
washed with 20 column volumes of the same buffer without detergent
at 4°C [19]. Elution of the target protein was achieved with 250 mM
imidazole. The fusion protein was cut by addition of thrombin (1 U of
thrombin cleaves 5 mg of protein when incubated at room temperature
for 16 hours) to remove the His-tag. The mixture was further purified
using cobalt-charged chelating sepharose resin to remove incompletely
digested material and the free His-tag. The final protein product was
dialyzed in PBS and stored at 4°C.
Flow Cytometry Analysis
For the analysis of gp240 expression, flow cytometry analysis of cells
stained with Abs was performed as described [20]. Briefly, 5 × 105 cells
were incubated for 1 hour on ice with anti-gp240 specific ZME-018
IgG2a (2 μg/100 μl in 1% BSA in PBS). Cells were then washed twice
with 0.5% BSA in PBS and incubated for an additional 30 minutes on
ice with an FITC-conjugated goat antimouse IgG mAb. After two
washes, cells were fixed in 3.7% paraformaldehyde and analyzed with
a FACSCalibur flow cytometer using CellQuest software (BD Bio-
sciences, Mountain View, CA). Use mouse IgG2a as an isotype control.
Enzyme-Linked Immunosorbent Assay (ELISA) and
Cytotoxicity Assay of IκBα/scFvMEL to gp240 Positive
Melanoma Cells
The 96-well enzyme-linked immunosorbent assay (ELISA) plates
containing adherent melanoma and control cells (5 × 104 cells) were
used as described previously [21]. To detect the binding activity of
IκBα/scFvMEL, cells were incubated with purified IκBα/scFvMEL
at various concentrations for 1 hour at room temperature. After they
were washed, the cells were incubated with rabbit anti-scFvMEL Ab,
followed by the addition of goat antirabbit/HRP conjugate Ab. Finally,
the substrate (2,2′-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid)
solution containing 1 μl/ml 30% H2O2 was added to the wells. Ab-
sorbance at 405 nm was measured with ELISA reader (Bio-Tek Instru-
ments, Inc, Winooski, VT). Cytotoxicity of IκBα/scFvMEL on cells
were performed as previously described [21].
Internalization of IκBα/scFvMEL into Cells Expressing
gp240 Antigen
TheA375M, SK-MEL-5, andT-24 cell lines were added to polylysine-
coated 16-well chamber slides (Nunc, Rochester, NY) at 1 × 104 per
well and treated with different doses of IκBα/scFvMEL for 4 hours. Or
cells were plated at 1 × 106 per well on six-well plates and then treated
with IκBα/scFvMEL. Proteins bound to the cell surface were removed
by incubating with glycine buffer (500 mM NaCl and 0.1 M glycine,
pH 2.5) and neutralizing for 5 minutes with 0.5 M Tris (pH 7.4)
followed by washing with PBS. Immunoblot analysis and immuno-
fluorescence laser scanning microscopy were done as previously de-
scribed [22].
Immunoprecipitation and Western Blot Analysis
For immunoprecipitations and Western blot analysis, cells were
lysed in 50 mMTris (pH 8), 150 mMNaCl, 1%Nonidet P-40 buffer
containing protease inhibitors. Aliquots of cell lysates were either re-
solved in SDS-PAGE or were used for immunoprecipitations with the
indicated Abs or with protein G PLUS-agarose (Santa Cruz Biotechnol-
ogy, Inc). Proteins were transferred onto polyvinylidene difluoridemem-
branes and immunodetected with the indicated Abs. HRP-conjugated
secondary Abs and Enhanced Chemiluminescence Detection reagent
(AmershamPharmacia Biotech, Inc, Piscataway,NJ)were used to develop
the Western blots as previously described [18,23].
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSA) were performed by
incubating 15 μg of nuclear extracts for 30 minutes at room temper-
ature with α-32P-labeled NF-κB consensus oligonucleotides based on
conditions defined previously [24].
Immunocytochemistry for NF-κB p65 Localization
The effect of IκBα/scFvMEL on TNFα-induced nuclear transloca-
tion of p65 was examined by an immunocytochemical method using
an epifluorescence microscope (Labophot-2; Nikon Corp, Melville,
NY) as described previously [25].
NF-κB–Dependent Reporter Gene Expression Assay
The effect of IκBα/scFvMEL on NF-κB–dependent reporter gene
transcription induced by TNFα was analyzed by secretory alkaline phos-
phatase (SEAP) assay as previously described [26]. Briefly, A375M,
SK-MEL-5, and T-24 semiconfluent cells (3 × 105 cells per well) were
transiently cotransfected with pNF-κB-SEAP (0.5 μg) and the control
plasmid pCMV-FLAG1 (0.5 μg) for 24 hours using FuGENE 6 (Life
Technologies, Inc). We then treated the cells for 4 hours with IκBα/
scFvMEL and/or curcumin and then stimulated themwith 1 nMTNFα.
The cell culture medium was harvested after 24 hours of TNFα treat-
ment. The culture medium was analyzed for SEAP activity according
to the protocol essentially as described by the manufacturer (Clontech,
Palo Alto, CA) using a Victor 3 microplate reader (Perkin-Elmer,
Norwalk, CT).
Clonogenic Survival Assay
The effectiveness of the combination of IκBα/scFvMEL and ion-
izing radiation was assessed by clonogenic assay. Melanoma cells were
pretreated with either PBS or IκBα/scFvMEL (0.3 μM) for 2 hours.
Then, cells were irradiated with various doses of ionizing radiation
and were then processed for clonogenic cell survival assay [27]. After
treatment, cells were trypsinized and counted. Known cell numbers
were then replated in triplicate and returned to the incubator to al-
low macroscopic colony development. Colonies were stained with
crystal violet solution and counted after ∼14 days. The percentage
of plating efficiency and the fraction surviving a given treatment were
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calculated based on the survival of nonirradiated cells treated with the
agent in question.
Animal Model Studies
A375M xenograft model. Athymic (nu/nu) mice, 4 to 6 weeks old,
were obtained from Harlan Sprague Dawley (Indianapolis, IN). The
animals were maintained under specific pathogen-free conditions and
were used at 6 to 8 weeks. Animals were injected subcutaneously (right
flank) with 3 × 106 log-phase A375M melanoma cells, and tumors
were allowed to establish. Once tumors had reached a measurable size
(∼30-50 mm3), animals were treated (intravenously [i.v.], tail vein)
with either saline (control) or IκBα/scFvMEL fusion construct daily
for 10 days with a total dose of 100 mg/kg.
Localization of IκBα/scFvMEL after systemic administration. Mice
bearing A375M xenograft tumors (subcutaneously, flank) were adminis-
tered IκBα/scFvMEL (100mg/kg) as an i.v. injection (tail vein). Twenty-
four hours after the last administration, animals were killed; tumor
tissues were removed, fixed by formalin, and stained by hematoxylin
and eosin; and immunohistochemical staining for IκBα/scFvMELwas
detected by rabbit anti-scFvMEL Ab from our core laboratory.
Regulation of antiapoptotic proteins. Mice bearing A375M xeno-
graft tumors were administered IκBα/scFvMEL (100mg/kg). Twenty-
four hours after the last administration, animals were killed and tumor
tissues were removed, rinsed by ice-cold PBS, and homogenized in ice-
cold lysis buffer containing protease inhibitors followed by centrifuge
at 14,000 rpm for 10minutes at 4°C to remove the tissue debris. Protein
concentrations of the supernatants were determined, equal amounts of
protein were separated by SDS-PAGE, and standard Western blot anal-
ysis were performed detected by Bcl-2 and Bcl-xL Abs.
Results
Isolation and Purification of the IκBα/scFvMEL
The IκBα/scFvMEL fusion construct was designed with a short,
flexible linker (G4S) bridging the IκBα and scFvMEL protein (Fig-
ure W1A). The thioredoxin tag containing the 6-His domain was engi-
neered to contain a thrombin recognition domain for facile, enzymatic
removal of the tag, leaving only two amino acid residues (glycine-serine)
at the N-terminus of the molecule. Two-phase extraction using a non-
ionic detergent, such as Triton X-114, is known to be a very effective
method for removing endotoxins from purified proteins [28]. We com-
bined affinity chromatography with a nonionic detergent washing step
to remove most of the endotoxin contaminants from the end product
[19]. An endotoxin reduction of less than 9 to 0.9 EU/mg was achieved
with virtually complete protein recovery. The Coomassie-stained SDS-
PAGE (Figure W1B) demonstrates that one-step binding and elution
from immobilizedmetal affinity chromatography (IMAC) resin resulted
in a relatively high level of purity from the bacterial lysate. We were able
to generate virtually complete cleavage of the thioredoxin tag from the
fusion protein. Re-exposure of the cleavage mixture to fresh IMAC resin
allowed the cleaved purification tag to bind, whereas the released IκBα/
scFvMEL fusion protein flowed through the column. The final material
migrated on SDS-PAGE with a molecular weight of 55 kDa and was
essentially free of contaminating proteins.
Analysis of gp240 Antigen (High–Molecular Weight
Melanoma-Associated Antigen) Expression in Various
Human Melanoma Cell Lines
To examine the expression of the gp240 antigen on melanoma cell
lines, melanoma cells were stained with parental mAb ZME-018 IgG2a
that specifically binds to the gp240 antigen. As shown in (FigureW2, A
and B), using the anti-gp240 Ab ZME-018, A375M cells show strongly
positive (98.9%) and SK-MEL-5 cells show less positive (46.4%) by
flow cytometry compared with the isotype-matched control (IgG 2a)
murine Ab. In contrast, the TXM-1 cells demonstrated weak binding
(4.6%) and the bladder cell line T-24 showed almost no binding to
the Ab by flow. Immunohistochemistry analysis confirmed strong, uni-
form staining on the A375M cells, whereas staining on the TXM-1 cells
showed no difference compared with the isotype control (FigureW2B).
ELISA result also showed the same pattern (Figure W2C). These data
demonstrated that the gp240 antigen was more highly expressed on
A375M, and there was a very low level of expression of the gp240 anti-
gen on TXM-1 and no expression on T-24.
Assessment of Cell-Binding Activity of the scFvMEL
Component of IκBα/scFvMEL
Because the gp240 antigen highly presents in melanoma A375M but
not in T-24, we further examined whether the IκBα/scFvMEL could
bind to antigen-positive cells. ELISA was performed to determine the
binding activity of the IκBα/scFvMEL to melanoma cells. The results
demonstrate that IκBα/scFvMEL bound to high-level gp240 antigen–
expressing melanoma A375M (Figure 1, A, C , and D) cell lines. How-
ever, the protein showed very less or did not bind to T-24 (Figure 1, B
and D), in which the gp240 antigen was not detected by ZME-018
mAb (FigureW2,A andC). To determine whether IκBα/scFvMEL rec-
ognize the same antigen of A375M to its parental mAb ZME-018, com-
petitive ELISA was performed by preincubating with a 10-fold higher
concentration of ZME-018 before IκBα/scFvMELwas added to the cell
surface. Figure 1C showed that ZME-018 did compete with IκBα/
scFvMEL to bind gp240 antigen on A375M cells.
IκBα/scFvMEL Specifically Is Internalized into gp240
Antigen–Positive Melanoma Cells
We next examined by Western blot and immunostaining whether
IκB/scFvMELwas specifically delivered into the cytoplasm of the gp240
antigen–positive melanoma cells. Human melanoma cells expressing
high levels of gp240 (A375M), lower levels (AAB527), and antigen-
negative cells (TXM-1) were treatedwith various doses of IκB/scFvMEL
for 2 hours. Cell surfaces were washed and stripped by addition of gly-
cine buffer (500 mM NaCl, 0.1 M glycine, pH 2.5) for 5 minutes to
remove excess fusion protein.Whole-cell lysates were detected byWest-
ern blot using a rabbit anti-IκBα Ab. The migration of authentic IκBα
and IκBα/scFvMEL are indicated on Figure 2, A, B, and C , by the
arrows. There was no internalization of IκBα/scFvMEL observed in
the TXM-1 and T-24 cells. In contrast, there were significant intracel-
lular concentrations of IκBα/scFvMEL in the A375M cells within
2 hours of exposure to doses of 50 to 200 nM. Internalization of
IκBα/scFvMEL by AAB527 cells showed a higher dose dependence
over the range tested. There did not seem to be a breakdown of endog-
enous IκBα within the 2-hour time course because the basal levels of
IκBα did not seem to be affected by the treatment with IκBα/scFvMEL.
Figure 2B showed that 100 nM IκBα/scFvMEL for approximately
1.5 hours of treatment can mediate the internalization into A375M
cells. For the receptor-negative T-24 cells, only a weak bandwas detected
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Figure 2. Internalization of IκBα/scFvMEL into antigen-positive and -negative human melanoma cells. (A) IκBα/scFvMEL specifically internalized
into gp240-positive cells. Cellswere treatedwith different concentrations of IκBα/scFvMEL for 2 hours. Cell surfaceswerewashed and stripped to
remove excess fusion protein.Whole-cell lysateswere analyzed byWestern blot using anti-IκBαAb. (B) Time course of IκBα/scFvMEL internalized
intogp240-positive cells.A375MandT-24cellswere treatedwith100nMof IκBα/scFvMEL for the indicated times.Cell surfaceswerewashedand
stripped to remove excess fusion protein. Whole-cell lysates were analyzed by Western blot using anti-IκBα Ab. The arrows demonstrate the
migration positions of IκBα/scFvMEL and native IκBα, respectively. (C) Internalization of IκBα/scFvMEL into A375M cells analyzed by pulse chase
analysis. A375Mand T-24 cellswere pretreatedwith 100 nMof IκBα/scFvMEL for 2.5 hours, thenwashedwith PBS twice, andwere addedwith a
freshmedium. After culturing for different times, cells were lysed, and proteins were analyzed byWestern blot using anti-IκBα Ab. (D) 1, Internal-
ization of IκBα/scFvMEL into A375M, SK-MEL-5, and T-24 cells was visualized using confocal microscopy (original magnification, ×200). 2, Time-
dependent internalization of IκBα/scFvMEL into A375M cells was visualized using confocal microscopy (original magnification, ×200).
Figure 1. IκBα/scFvMEL specifically binds to gp240 antigen–positive melanoma cells, as assessed by ELISA. IκBα/scFvMEL binds to the
(A) gp240 antigen–positive cell line A375M, (B) gp240-negative cell line T-24, (C) A375M but was competed by preadded ZME-018 to the
cells, and (D) gp240-positive and –negative cell lines. scFvMEL/rGel as a positive control protein.
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up to 12 hours of treatment. Pulse chase analysis showed that after
2.5 hours of 100 nM IκBα/scFvMEL treatment, the fusion construct
could be maintained in the cytoplasm up to 9 hours on A375M; how-
ever, for T-24, we could only detect the weak signal after immediately
removing the protein solution (Figure 2C ). The IκBα moiety of the
fusion construct was efficiently delivered into the cytosol of gp240
antigen–positive A375M, but less was delivered into SK-MEL-5 (because
of less gp240 expression level; FigureW2,A andC) andwas not delivered
into gp240 antigen–negative T-24 cells showed dose dependent, as visu-
alized by confocal microscope detected using anti-scFvMEL Ab (Fig-
ure 2D1). Moreover, the internalization effect of IκBα/scFvMEL into
A375M was time-dependent as confirmed by confocal microscopy (Fig-
ure 2D2). These strongly demonstrated that the gp240 expression on
the tumor cell surface and the binding of IκBα/scFvMEL to the gp240
antigen are responsible for the internalization of the IκBα/scFvMEL.
IκBα/scFvMEL Associates with the p65 Subunit of NF-κB and
Inhibits NF-κB Activation Induced by TNFα
It is known that the inhibitor proteins IκBα tightly regulate the
transcriptional activity of p65– and c-Rel–containing NF-κB dimers.
In resting cells, IκBα binds extremely tightly to NF-κB, preventing its
nuclear accumulation and association with DNA [29]. To assess
whether exogenously entered IκBα/scFvMEL can interact with cellular
NF-κB, A375M cells were treated with 100 nM IκBα/scFvMEL over-
night, and the p65 subunit of NF-κB was immunoprecipitated. IκBα/
scFvMEL coimmunoprecipitated with p65, suggesting its association
Figure 3. IκBα/scFvMEL associates with NF-κB and inhibits TNFα-induced NF-κB activation. (A) IκBα/scFvMEL associates with NF-κB.
A375M cells were left untreated or were incubated with 100 nM IκBα/scFvMEL overnight and then stimulated with or without 0.5 nM
TNFα for 30 minutes. Cells were washed and lysed, and the NF-κB p65 was immunoprecipitated. Immune complexes were resolved in
SDS-PAGE, transferred onto a membrane, and sequentially probed with anti-IκBα, anti-p50, and anti-p65 Abs. (B) IκBα/scFvMEL specif-
ically inhibits TNFα-induced NF-κB activation on A375M but not T-24 cells. A375M and T-24 cells were pretreated with 200 and/or 400 nM
IκBα/scFvMEL for 24 hours at 37°C and then stimulated with 1 nM TNFα for 20minutes. Nucleus extracts were then prepared and assayed
for NF-κB by EMSA. (C) Time- and dose-dependent inhibition of TNFα-induced NF-κB activation by IκBα/scFvMEL. A375M cells were prein-
cubatedwith 400 nM IκBα/scFvMEL for the indicated times, or A375M cells were treatedwith different doses (5, 25, 50, 100, 200, or 400 nM)
of IκBα/scFvMEL for 24 hours and then induced by 1 nM TNFα for 20 minutes, and nucleus extracts were examined for NF-κB activation by
EMSA. NT indicates not treated.
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with endogenous NF-κB (Figure 3A). Because TNFα is one of the most
potent activators of NF-κB and the mechanism of activation is relatively
well established, we examined the effect of IκBα/scFvMEL on TNFα-
inducedNF-κB activation in A375MandT-24 cells. A375M stimulated
with 1 nM TNFα for 20 minutes can make maximum induction of
NF-κB activity (Figure W3). A375M and T-24 cells were pretreated
with 200 and/or 400 nM IκBα/scFvMEL for 24 hours and then stim-
ulated with TNFα. As indicated by EMSA, IκBα/scFvMEL can al-
most specifically fully inhibit NF-κB activity in A375M but not
T-24 cells (Figure 3B). Incubating with different doses and times of
IκBα/scFvMEL on A375M, IκBα/scFvMEL suppressed TNFα-
induced NF-κB activation in a dose- and time-dependent manner
(Figure 3C ).
IκBα/scFvMEL Specifically Inhibits TNFα-Induced Nuclear
Translocation of p65
In the next step of the NF-κB activation cascade, TNFα induces
the phosphorylation of p65, which is required for its transcriptional
activity. After phosphorylation, the p65 subunit is translocated to the
nucleus. To assess whether IκBα/scFvMEL can inhibit the subunit of
NF-κB translocation, A375M cells were either untreated or pretreated
with 200 nM IκBα/scFvMEL for 24 hours and were then stimulated
with 1 nM TNFα for different times. Nucleus extracts were prepared
and analyzed byWestern blot using Abs against p65 and p50.Western
blot analysis showed that IκBα/scFvMEL partially blocked the
TNFα-induced nuclear translocation of p65 in a time-dependent
manner in A375M cells (Figure 4A). Immunocytochemistry also con-
firmed this finding (Figure 4B), that is, IκBα/scFvMEL alone would
not induce the p65 translocation in both cell types. However, IκBα/
scFvMEL could specifically inhibit TNFα-stimulated p65 subunit
translocation into the nucleus in A375M but not in T-24 cells.
IκBα/scFvMEL Specifically Inhibits
NF-κB–Driven Transcription
On stimulation, NF-κB–bound IκBα is specifically phosphorylated
(by the IκB kinase), ubiquitinated, and degraded by the proteasome.
NF-κB then enters the nucleus, binds DNA, and regulates transcrip-
tion of its numerous target genes [29]. To determine whether IκBα/
scFvMEL could inhibit the transcriptional activity of NF-κB, TNFα-
induced NF-κB–dependent reporter gene expression assay was used.
We transiently transfected the cells with the NF-κB–regulated SEAP
reporter construct, incubated them with IκBα/scFvMEL, and then
stimulated with 1 nM TNFα. An almost 12-fold increase in SEAP ac-
tivity over the cells’ control in A375M cells was observed on stimula-
tion with 1 nM TNFα, and IκBα/scFvMEL exogenously added
inhibited TNFα-induced SEAP production in a dose-dependent man-
ner on A375M (Figure 5A) and SK-MEL-5 (Figure 5B) cells. The pres-
ence of 10 μM curcumin in the culture medium resulted in only
approximately 30% inhibition, but curcumin did a better job on T-24
cells (Figure 5, A and C). Addition of up to 400 nM IκBα/scFvMEL to
the culture medium had less effect on TNFα-induced SEAP production
on T-24 cells (Figure 4C). These results show that IκBα/scFvMEL spe-
cifically represses NF-κB–dependent reporter gene expression induced
by TNFα directly related to the gp240 receptor status on the cells. Be-
sides the reporter gene, we also checked the expression of the two impor-
tant apoptosis-related genes downstream of the NF-κB cascade. Cells
were pretreated with IκBα/scFvMEL for 24 hours and then treated
with TNFα for different times. Whole-cell extracts were prepared
Figure 4. IκBα/scFvMEL inhibits TNFα-induced nuclear translocation of p65. (A) A375Mcellswere either untreated or pretreatedwith 200 nM
IκBα/scFvMEL for 24 hours and then treated with 1 nM TNFα for the indicated times. Nucleus extracts were prepared and analyzed byWest-
ern blot using Abs against p65 and p50. As a nuclear protein loading control, themembranewas blotted with anti-poly (ADP-ribose) polymer-
ase (PARP) Ab. (B) Immunocytochemical analysis of NF-κB p65 localization. A375Mand T-24 cellswere not treated or pretreatedwith 200 nM
IκBα/scFvMEL for 4 hours, thenstimulatedwith 1 nMTNFα, and subjected to immunocytochemistry analysis.NF-κBp65werestained red and
counterstained for nuclei with Hoechst 33342 (50 ng/ml) for 5 minutes.
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and analyzed by Western blot analysis for Bcl-2 and Bax expression
(Figure 5D). IκBα/scFvMEL inhibited TNFα-induced antiapoptotic
protein Bcl2 expression and upregulated proapoptotic protein Bax ex-
pression separately. The results further strengthen the validation of our
postulate that IκBα/scFvMEL has a role in blocking TNFα-induced
NF-κB transcription.
Cytotoxic Effects of IκBα/scFvMEL on Log-Phase Cells
We assessed the effect of IκBα/scFvMEL antigen-positive (A375M,
AAB527, andA375SM) and antigen-negativemelanoma cells (TXM-1)
in log-phase culture for 72 hours of incubation. As shown in FigureW4,
there was little toxicity of either IκBα or the IκBα/scFvMEL construct
at doses up to 100 nM.
Selective Effect of IκBα/scFvMEL on Sensitivity
to Ionizing Radiation
We next treated A375M and TXM-1 cells with IκBα/scFvMEL
alone, with radiation exposure (4 Gy) alone, or a combination of the
two. As Figure 6A shows, radiation exposure induced NF-κB activity
above basal levels, and treatment with IκBα/scFvMEL was able to
completely abrogate the basal activity and the radiation-induced com-
ponent. We added a second line (A375SM) that is gp240-positive, a
more metastatic variant, and showed a higher induction of NF-κB
activity with radiation exposure. Treatment with IκBα/scFvMEL was
also able to suppress both basal and radiation-induced activity. TXM-1
cells were found to express low basal levels of NF-κB, and these levels
were unchanged with exposure to radiation, to IκBα/scFvMEL, or to
a combination of both. In addition, we examined the activity of Bcl-2
and Bcl-xL proteins, which are downstream of NF-κB. As shown in
Figure 6B, treatment with 200 nM of the IκBα/scFvMEL reduced the
activity of both Bcl-2 and Bcl-xL proteins in A375M cells. As expected,
there was no effect of treatment on TXM-1 cells.
We next examined the ability of the IκB/scFvMEL to sensitize mel-
anoma cells to ionizing radiation in a clonogenic survival assay. Cells
were treated with 300 nM IκBα/scFvMEL and were subjected to ion-
izing radiation either at a 2- or 4-Gy dose. As shown in Figure 6C , there
was no effect of IκBα/scFvMEL on the clonogenic potential of antigen-
negative (TXM-1) melanoma cells at either 2 or 4 Gy, although the ra-
diation itself was able to reduce survival by almost 90%. Treatment of
A375M cells with IκBα/scFvMEL was shown to result in a statistically
significant decrease in clonogenic survival at both the 2- and 4-Gy dose
levels. The survival factor was reduced from 50.2% ± 1.06% in vehicle-
treated A375M cells to 35.4% ± 2.75% in IκBα/scFvMEL-treated cells
at 2 Gy (P < .05) and from 19.8% ± 2.50% in vehicle–treated cells to
7.4% ± 0.74% in IκBα/scFvMEL–treated cells at 4 Gy (P < .05).
In Vivo Antitumor Effects of IκB/scFvMEL on Nude Mice
Bearing A375M Xenografts
Mice bearing well-established A375M xenografts were treated (i.v.)
with saline or IκB/scFvMEL construct (100 mg/kg total dose) divided
Figure 5. IκBα/scFvMEL inhibits TNF-induced expression of NF-κB–dependent gene. Cellswere transiently transfectedwith aNF-κB–SEAP
plasmid and then pretreated with the indicated concentration of IκBα/scFvMEL and/or curcumin for 4 hours and then coincubated with
1 nM TNF for 24 hours. Cell supernatants were collected and assayed for SEAP activity: (A) A375M, (B) SK-MEL-5, and (C) T-24. (D) IκBα/
scFvMEL inhibits TNFα-induced expression of NF-κB–dependent antiapoptotic protein Bcl-2 and upregulates the expression of proapop-
totic protein Bax. A375M cells were incubated with 400 nM IκBα/scFvMEL for 24 hours and then treated with 1 nM TNFα for the indicated
times. Whole-cell lysates were prepared and analyzed by Western blot analysis using the indicated Abs. NT indicates not treated.
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into 10 daily doses. As shown in Figure 7A, there was a significant sup-
pression of tumor growth in the treated group, which persisted long
after the end of i.v. administration. As shown in Figure W5, at the
end of the 10-day treatment period, tumors from the control mice were
almost four-fold larger than tumors from mice treated with the fusion
construct. Thereafter, the saline-treated group continued rapid growth,
reaching approximately 2300 mm3 (mean) compared with the treat-
ment group (130 mm3) at day 50. The mice were then killed, tumor
specimens were assessed by IHC, and the intratumor activities of several
signaling events downstream ofNF-κB including Bcl-2 and Bcl-xLwere
assessed by Western blot (Figure 7B).
Analysis of tumor xenografts at day 50 (>30 days after the last injec-
tion) by immunohistochemistry (Figure 7C ) showed that the scFvMEL
Ab could be easily detected tumor xenografts demonstrating tumor lo-
calization of the IκB/scFvMEL construct. There was no detectable
change observed in the hematoxylin and eosin stain performed on the
same samples. Analysis of various signaling proteins in tumors treated
with saline or the IκB/scFvMEL construct (Figure 7B) showed no sig-
nificant change in p53, GADD45, cyclin D1, or BAX levels. We did
observe a decrease in levels of Bcl2 and Bcl-xL, consistent with the ob-
servations in tissue-cultured cells. In addition, we also found a slight de-
crease in levels of MDM-2.
Discussion
With the slow progress in finding an effective treatment of melanoma
in recent years, the expectation is that novel treatment agents that tar-
get signaling pathways essential for melanoma growth and invasion
may offer hope for an otherwise dismal disease. It is now clear that
melanoma exhibits constitutive activation of NF-κB. This activation
of NF-κB leads to endogenous expression of a number of factors asso-
ciated with escape from apoptosis, tumorigenesis, and metastasis. It is
well understood that NF-κB plays a role in tumor growth, metastatic
spread, apoptosis, chemoresistance, and radioresistance. Given its
dominance in the regulation of a number of growth signals and in
the immune and inflammatory response as well as in the growth of
neoplastic cells, NF-κB has been the subject of numerous strategies
to develop regulators of its activity. Yan Liu et al. [30] have described
a small peptide motif capable of inhibiting nuclear transport of NF-κB
and, when introduced into mice, was shown to suppress the produc-
tion of the proinflammatory cytokines TNFα and interferon-γ. Other
approaches to regulating NF-κB activity involve regulating IκB phos-
phorylation [9] and inhibiting the p50-mediated binding to DNA
complex [31,32]. Small molecule inhibitors of NF-κB activity include
DHMEQ [33], 15-deoxy-Δ12,14-prostaglandin J(2) [34], CP-1158
[35], linoleic acid derivatives [36], triterpenoid derivatives [37], CSA
[38], curcumin [39,40], and its derivatives [41]. Reagents like sulindac
or other nonsteroidal anti-inflammatory drugs offer potential therapeu-
tic reagents for human tumors [42,43]. Recent progress in developing
specific inhibitors of NF-κB has resulted in designing inhibitors of IκB
kinases. Another class of NF-κB pathway inhibitors identified is the pro-
teasome inhibitors. Although studies describe a decrease in transcription
factor activity, most of these agents target other key regulatory molecules
Figure 6. Treatment with IκBα/scFvMEL sensitizes gp240 antigen–positive melanoma cells to ionizing radiation. (A) Treatment with IκBα/
scFvMEL specifically blocks constitutive and radiation-induced NF-κB activity in gp240 antigen–positive A375M cells but not on gp240
antigen–negative TXM-1 melanoma cells. A375M, A375SM, and TXM-1 cells were left untreated, exposed to 4 Gy, and pretreated with
300 nM IκBα/scFvMEL for 2.5 hours or a combination of IκBα/scFvMEL and radiation. Cells were harvested 2 hours after irradiation for
analysis by EMSA. (B) Decrease in levels of Bcl-2 and Bcl-xL in A375M but not TXM-1 cells after treatment with 200 nM IκBα/scFvMEL.
Western blot analysis for Bcl-2 and Bcl-XL in A375M and TXM-1 cells treatedwith 200 nM IκBα/scFvMEL for 4 hours. (C) Radiosensitization
by IκBα/scFvMEL was based on clonogenic cell survival assays. A375M and TXM-1 cells were pretreated with IκBα/scFvMEL (300 nM for
2 hours), the drug was washed off, and cells were irradiated at various doses and plated for clonogenic cell survival assay. Observed
sensitizations were statistically significant at 2-, 4-, and 6-Gy dosage groups on A375M cells (P< .05; the results were analyzed from three
experiments). No statistically significant sensitization was observed in gp240 antigen–negative TXM-1 cells (P > .05). Treatment of cells
with the construct alone had no effect on survival (data not shown).
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along with NF-κB, rendering it difficult to discern the specific role of
NF-κB in the progression of the disease and its attribute as a therapeutic
target. Amajor concern about using the previouslymentioned inhibitors
of NF-κB is the lack of specificity or selectivity. The current study differs
from previously described molecules in that the effects described are
clearly dependent on the cellular targeting and internalization of the fu-
sion construct. These inhibitory effects onNF-κB can clearly be targeted
in vitro to selected sites using an appropriate construct.
As far as we are aware, there have been no studies that have demon-
strated cell-specific delivery of agents capable of inhibiting the NF-κB
transcription factor. Tumor-targeting studies have demonstrated proof of
concept in this particular fusion construct. The high–molecular weight
melanoma-associated glycoprotein gp240 has previously been demon-
strated in a majority (80%) of melanoma cell lines and fresh tumor sam-
ples [44]. More importantly, the gp240 antigen is either not expressed or
expressed in low level in normal cells [45,46], thus making this an inter-
esting target for therapeutic intervention. mAbs targeting the gp240 an-
tigen, such as ZME-018 and 9.2.27, have been extensively studied in
melanoma patients and have demonstrated in numerous clinical trials
an impressive ability to localize inmetastatic tumors after systemic admin-
istration [45,46]. In addition, a variety of recombinant fusion constructs
have been generated from the murine Ab designated ZME-018, which
targets this protein.
The current study describes a fusion construct composed of the
natural inhibitor of intracellular NF-κB activity (IκBα) and an anti-
melanoma single-chain Ab scFvMEL, IκBα/scFvMEL. We clearly
demonstrate that intracellular delivery of the IκBα/scFvMEL molecule
can blockTNFα-mediatedNF-κB activation. And also IκBα/scFvMEL
can specifically inhibit both endogenous and radiation-induced up-
regulation of NF-κB activity. The inhibitory effect of IκBα/scFvMEL
directly correlated with physical association with the subunit of NF-κB
complex (Figure 3A), and this association could not be disrupted by
TNFα stimulation (Figure 3A, lane 3). As a natural inhibitor of NF-
κB, when NF-κB is activated with activating signals, IκBα phosphory-
lates, ubiquitinates, and degrades IκB by the 26S proteasome. Stimulated
cells with TNFα caused the degradation of endogenous IκBα but not
IκBα/scFvMEL (data not shown), which indicated that IκBα/scFvMEL
most likely exerts its inhibitory function, by associating nonreversibly
with the NF-κB components inside the cells. As a super suppressor
of NF-κB, we found that IκBα/scFvMEL inhibits TNFα-stimulated
NF-κB p65 translocation into the nucleus and also NF-κB–dependent
reporter gene expression. And also, we have shown that IκBα/scFvMEL
Figure 7. IκBα/scFvMEL demonstrates antitumor activity in a xenograft melanoma model. (A) Nude mice bearing human melanoma
(A375M) tumors were treated i.v. with either saline (control) or IκBα/scFvMEL (100 mg/kg; total dose) for 10 consecutive days (arrows).
The treatment of mice bearing established (30-50 mm3) tumors with IκBα/scFvMEL at a total dose of 100 mg/kg resulted in potent tumor
suppression and complete tumor regression of all lesions. In contrast, all mice treated with either saline showed rapid tumor growth. (B)
Intratumor activities of several signaling events downstream of NF-κB including Bcl-2 and Bcl-xL were assessed byWestern blot. (C) IκBα/
scFvMEL is localized or internalized in tumor tissues. Twenty-four hours after the last dose, animals were killed, and tumor tissues were
removed, fixed, and stained by immunohistochemical staining for IκBα/scFvMEL detected by either anti-scFvMEL Ab. Localization and
internalization of IκBα/scFvMEL were observed in tumor tissues in the treatment group but not in the control group.
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inhibited tumor growth in the A375M xenograft model (Figure 7A).
Because NF-κB activation has an antiapoptotic role in tumor cells,
it is possible that inhibition of NF-κB activation would regulate the
apoptosis-relating gene expression.We demonstrated that IκBα/scFvMEL
can downregulate the downstream signals of Bcl-2 and Bcl-xL (Fig-
ure 6B) and upregulate Bax (Figure 5D). We also observed a decrease
in levels of Bcl-2 and Bcl-XL signaling events downstream of NF-κB in
the tumor model (Figure7B). Suppression of NF-κB has been impli-
cated in chemoprevention; studies with the IκBα/scFvMEL demon-
strate that the agent can augment the radioresponse of antigen-positive
melanoma cells to ionizing radiation.
The relationship of melanoma metastasis and inflammation has
been well understood [47]. The pivotal role of NF-κB in inflammation
is well established, and considerable efforts have been made to fully
understand its regulation and to develop agents that specifically inhibit
its action. IκBα, in its wild type andmutated forms, represents a specific
inhibitor and has been used in experimental system to inhibit NF-κB
activity. In most of the investigations, IκBα was expressed using an ad-
enoviral gene delivery system. However, today, delivery of genes in vivo
with viral vectors with the aim to regulate signaling pathways has the
following disadvantages: inadequate control over expression levels, irre-
versibility, and introduction into cells irrelevant and in many cases un-
wanted genetic material. Moreover, the use of this technology for the
treatment of inflammatory conditions possesses the additional disadvan-
tage of inflammation and/or immune response elicited by the viral vec-
tor, especially in the case of adenoviruses, which may limit their use in
the clinic.Here, we describe a novel way to introduce the super-repressor
IκBα inhibitor into melanoma cells to inhibit aberrant NF-κB.
Currently, there are several approved treatments for metastatic mel-
anoma, including chemotherapy and biologic therapy as both single
treatments and in combination, but none is associated with a signifi-
cant increase in survival. One of the main problems with melanoma
treatment is chemotherapeutic resistance. Melanoma tumors and cul-
tured cell lines are relatively resistant to the cytotoxic effects of ionizing
radiation, thereby limiting the use of radiotherapy for the clinical treat-
ment of melanoma. Munshi et al. [48] showed that inhibition of con-
stitutively activated nuclear factor-κB radiosensitizes human melanoma
cells. Controlling the transcript factor NF-κB [49] and tumor immu-
notherapy in melanoma [50] is a promising way of prevention. IκBα/
scFvMEL presents a promising targeting molecule to manipulate
NF-κB activity in rational combinations with ionizing radiation, and
it may improve the efficacy of radiotherapy for melanoma.
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Figure W1. Construction schematic and SDS-PAGE of IκBα/scFvMEL. (A) Construction schematic for the IκBα/scFvMEL fusion
protein. A 20-kDa thioredoxin (Trx) containing a His-6 tagwas cloned upstream of the target fusion protein. This tagwas used for
IMAC. The tag also contained a thrombin recognition sequence for enzymatic release of the target protein. The position of the
enzymatic cleavage in this sequence is shown by the red line. (B) SDS-PAGE of purified IκBα/scFvMEL. As described in the
Materials and Methods, bacterial paste was lysed to release soluble protein and chromatographed on IMAC. The resulting ma-
terial was then digested by exposing to thrombin, and the resulting fusion protein was purified as described. The final product
demonstrated a molecular weight of 55 kDa and was essentially free of the released tag and contaminating proteins.
Figure W2. Expression of gp240 antigen on humanmelanoma cell lines. (A) gp240 expression analysis by flowcytometry. A375M,
SK-MEL-5, and T-24 cells were incubated with anti-gp240–specific ZME-018 IgG2a followed by FITC-conjugated goat antimouse
IgGmAb andwere analyzedwith a FACSCalibur flow cytometer. Usemouse IgG2a as an isotype control. (B) Immunohistochemical
stainingof gp240 on the surface ofmelanomacells. A375Mand TXM-1 cellswere first incubatedwith ZME-018 and then incubated
with an FITC-conjugated goat antimouse IgGmAb. Cells were fixed in 3.7% formaldehyde and permeabilized in 0.2%Triton X-100.
The slides were mounted with 1,4-diazobicyclo-{2,2,2}-octane containing 1 μg/ml propidium iodide and analyzed under a Nikon
Eclipse TS-100 fluorescence microscope (Nikon, Kingston-upon-Thames, UK). The same samples were analyzed by FACSCalibur
flow cytometer. (C) ELISA binding assay of gp240. The 96-well ELISA plates containing adherent A375M, SK-MEL-5 melanoma,
and T-24 bladder cells (5 × 104 cells/well) were blocked by the addition of a solution containing 5% BSA for 1 hour. Cells were
incubated with ZME-018 at various concentrations for 1 hour at room temperature. After washing, the cells were incubated with
an HRP-conjugated goat antimouse IgG mAb. Finally, the substrate solution 2,2′-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid
containing 1 μl/ml 30% H2O2 was added to the wells. Absorbance at 405 nm was measured after 10 minutes.
Figure W3. Dose- and time-dependent TNFα-stimulated NF-κB activation on
A375M cells. (A) A375M cells were treated with different doses of TNFα for
30 minutes. (B) A375M cells were treated with 1 nM TNFα for the indicated
times. Nucleus extracts were then prepared and assayed for NF-κB by EMSA.
Figure W4. Comparative cytotoxic effects of scFvMEL/TNF, TNF,
IκBα, and IκBα/scFvMEL against A375M cells.
Figure W5. At the end of the 10-day treatment period, tumors from control mice
were almost four-fold larger than tumors from mice treated with IκBα/scFvMEL
construct. Thereafter, the saline-treated group continued rapid growth, reaching
approximately 2300mm3 (mean) comparedwith the treatment group (130mm3)
at day 50.
